ABOUT RESVINET FOUNDATIONRSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries.
ReSViNET Foundation a financially and otherwise independent regulated entity. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward. Advances in RSV vaccine developmentApril 2018 - Advances in knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have revolutionized RSV vaccine development by providing a new target for preventive interventions. It is explained in this video, which was made by Djonie Jacobsen; Nienke Mombarg and Charlotte Wiersma, students from De Streek school in Ede, The Netherlands.
ReSViNET is proud to announce new publication in Lancet Infectious Diseases
26 June 2018 - We are happy to share with you that our manuscript "The RSV Vaccine Landscape: Lessons from the Graveyard and Promising Candidates” has been published online in the Lancet Infectious Diseases.
The aim of the manuscript is to give a comprehensive overview of vaccine candidates in clinical development, including maternal vaccine candidates. We hope you will enjoy reading the manuscript and look forward to receiving any questions or feedback. www.ncbi.nlm.nih.gov/pubmed/29914800 Official Launch of the ReSViNET Foundation
ZEIST, THE NETHERLANDS, 15 May 2018 – Today, we proudly announce the Official Launch of the ReSViNET Foundation as a registered not-for-profit entity under Dutch law. After 4 years of building and shaping the network and months of preparation, the ReSViNET Foundation has officially been founded.
As a foundation ReSViNET is now a financially and otherwise independent regulated entity which represents a major milestone for the entire ReSViNET project. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward. We are exceptionally proud to be the first official Respiratory Syncytial Virus (RSV) foundation and aim to foster global collaboration among ... Beautiful impression video - RSV Vaccines for the World conference 2017ReSViNET sites |
RESVINET BROCHUREPAPER OF THE MONTHThe respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, Mc Lellan JS, Englund JA, Meijas A, KArron RA, Simōes EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulus NG, Vekenmans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ, Respiratory Syncytial Virus Network (ReSViNET) Foundation. The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. 
ReSViNET scale APPDownload here RESVINET scale APP for pediatric respiratory assessment
|
